EL7.AI
StocksMedium•3 August 2026•
1 min read

Marriott and Biotech Firms Post Strong Q2 2026 Results

Key Facts

1Marriott International reported a 3.4% worldwide RevPAR increase with its development pipeline reaching a new record of 629,000 rooms.
2TG Therapeutics raised its full-year 2026 revenue guidance to $950 million driven by strong BRIUMVI sales.
3Luckin Coffee net revenues increased by 28.5% year-over-year to RMB15.9 billion.

Amid a period of sustained recovery in the hospitality and healthcare sectors, Q2 2026 earnings reports highlighted robust performance from major players led by Marriott International and TG Therapeutics. Marriott reported a 3.4% worldwide increase in revenue per available room (RevPAR), with its development pipeline hitting a record 629,000 rooms. Simultaneously, TG Therapeutics raised its full-year 2026 revenue guidance to $950 million, citing strong sales of its BRIUMVI treatment, while Luckin Coffee saw net revenues surge by 28.5%.

These results reflect resilient consumer spending and high demand for medical innovation despite broader economic shifts. In the retail sector, Luckin Coffee's revenues reached RMB15.9 billion, signaling continued expansion in Asian markets. This corporate momentum coincides with biotech advancements, as Krystal Biotech moves forward with plans for the commercial expansion of its gene therapy treatments in Europe and other international jurisdictions.

In the markets, Marriott (0JYW.L) stood at $376.26 at the close of July 30, 2026, having reached a day high of $395. Investors are now monitoring the impact of recent monetary policy, following the Federal Reserve's decision on July 29, 2026, to hold interest rates at 3.75%, a key factor influencing future financing costs for large-scale development pipelines.